Tirzepatide Brand Names
Tirzepatide is marketed under two brand names by Eli Lilly: Mounjaro® for type 2 diabetes mellitus and Zepbound® for chronic weight management in adults with obesity. 1, 2, 3, 4
Brand-Specific Indications
Mounjaro®
- FDA approved in May 2022 for type 2 diabetes mellitus 1, 4, 5
- Available as once-weekly subcutaneous injection at doses of 5,10, and 15 mg 6
- Demonstrated A1C reduction of 1.9% to 2% with >87% of patients reaching A1C target of <7% 6
Zepbound®
- FDA approved in November 2023 for chronic weight management 1, 3
- Same dosing regimen as Mounjaro (5,10,15 mg weekly) 2
- Indicated for adults with obesity or overweight with at least one weight-related comorbidity 1
- Additionally approved in December 2024 as the first prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity 6
Clinical Context
Both formulations contain the same active ingredient—tirzepatide, a dual GIP/GLP-1 receptor agonist—but are marketed under different brand names based on their primary indication 6. The distinction is primarily regulatory and insurance-related rather than pharmacological.
Key efficacy data:
- Weight reduction of 22.5% at 72 weeks with 15 mg dose in obesity trials 6
- In patients with type 2 diabetes and obesity, weight reduction of 12.8-14.7% with 10-15 mg doses 6
- Formulated as once-weekly subcutaneous injection with half-life of 116.7 hours 6
The medication is titrated monthly from a starting dose of 2.5 mg weekly to a maximum of 15 mg weekly 6.